Advice
in the absence of a submission from the holder of the marketing authorisation
capsaicin (Qutenza®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice109KB (PDF)
Medicine details
- Medicine name:
- capsaicin (Qutenza)
- SMC ID:
- 1140/16
- Indication:
- Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 March 2016